Replies to post #331906 on NorthWest Biotherapeutics Inc (NWBO)

[jammyjames]

not bad but not quite as good as the DCVax-L blended data at 18 months.

It's a fairly comparable patient population as they also have mainly gross resection since the exclusion criteria states:

"Presence of greater than 1 cm x 1 cm residual tumor enhancement on postoperative MRI"

https://clinicaltrials.gov/ct2/show/NCT03491683